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Vaccination against tuberculosis in 
badgers and cattle: an overview of the 
challenges, developments and current 
research priorities in Great Britain
M. A. Chambers, S. P. Carter, G. J. Wilson, G. Jones, E. Brown, R. G. Hewinson,  
M. Vordermeier
Bovine tuberculosis (TB) is a significant threat to the cattle industry in England and Wales. It is 
widely acknowledged that a combination of measures targeting both cattle and wildlife will 
be required to eradicate bovine TB or reduce its prevalence until European official freedom 
status is achieved. Vaccination of cattle and/or badgers could contribute to bovine TB control 
in Great Britain, although there are significant gaps in our knowledge regarding the impact 
that vaccination would actually have on bovine TB incidence. Laboratory studies have 
demonstrated that vaccination with BCG can reduce the progression and severity of TB in both 
badgers and cattle. This is encouraging in terms of the prospect of a sustained vaccination 
programme achieving reductions in disease prevalence; however, developing vaccines for 
tackling the problem of bovine TB is challenging, time-consuming and resource-intensive, as 
this review article sets out to explain.
M. A. Chambers, BSc, PhD, 
School of Veterinary Medicine, 
University of Surrey, Surrey GU2 7XH, 
UK and AHVLA, Addlestone, Surrey 
KT15 3NB, UK
S. P. Carter, BSc, PhD,  
G. J. Wilson, BSc, PhD, 
AHVLA, Woodchester Park, Tinkley 
Lane, Stonehouse, Gloucestershire 
GL10 3UJ
G. Jones, BSc, PhD,
R. G. Hewinson, BSc, DPhil,  
M. Vordermeier, BSc, PhD, 
AHVLA, Addlestone, Surrey KT15 3NB, 
UK 
E. Brown, MSc, MA, VetMB MRCVS, 
Veterinary and Science Policy Advice, 
AHVLA, c/o Defra, 17 Smith Square, 
Nobel House, London SW1P 3JR, UK 
E-mail for correspondence: 
m.chambers@surrey.ac.uk 
Provenance: commissioned; externally 
peer reviewed
Veterinary Record (2014) doi: 10.1136/vr.102581
‘Bovine tuberculosis (TB) is one of the most complex animal 
health problems that the farming industry in Great Britain faces 
today’. This was the view of the Chief veterinary officer in 2006 
(Reynolds 2006) and, despite advances in our understanding of the 
disease and its epidemiology, this view still stands. The disease picture 
varies considerably within Great Britain; it is endemic and spreading 
in parts of england and Wales while Scotland has been officially 
TB-free since 2009 and only sees rare sporadic cases from imported 
cattle (Abernethy and others 2013). Despite regional differences, 
annual fluctuations and different ways of presenting the data, the 
overall picture of bovine TB incidence in Great Britain is that it has 
been on the increase since the early 1980s, although there is evidence 
that the increase may have plateaued in the last couple of years (Blake 
and Donnelly 2014). This implies that current TB control measures 
are slowing but not reversing the spread of disease. in addition, the 
Review
significant financial and emotional impact bovine TB has on farmers 
and the cost to government in control (bovine TB has cost the 
taxpayer £500 million in england alone in the past 10 years [Defra 
2014a]) means tackling this disease is a major animal health priority 
for government. Finally, its complex (and sometimes controversial) 
epidemiology, recently reviewed by Godfray and others (2013), means 
only a comprehensive, multifaceted eradication programme is likely to 
have a significant impact on infection levels. Readers are encouraged 
to refer to the review by Godfray and colleagues, which provides an 
excellent understanding of the natural science evidence base relevant 
to the control of bovine TB in Great Britain, including vaccination.
This review focuses on one component of the english and Welsh 
eradication programmes; namely vaccination. vaccination of cat-
tle and/or badgers could contribute to TB control in Great Britain 
(Delahay and others 2003, Wilson and others 2011). The aim of this 
review is to set out current knowledge and experience regarding the 
development and application of vaccines against bovine TB for badg-
ers and cattle. We highlight the most important gaps in our knowl-
edge, where empirical data are lacking, and some of the more signifi-
cant challenges to implementating vaccination. 
The aim of vaccination is to stimulate an immune response in 
the vaccinated animal, such that it is either resistant to infection or, if 
infection occurs, it is less susceptible to clinical disease and less likely 
to spread infection. even a vaccine that only partially protects animals 
to the extent that they are less infectious to other animals over their 
lifetime may still eventually reduce disease prevalence in the popula-
tion. There are significant gaps in our knowledge regarding the impact 
that the vaccination of either badgers or cattle could have in practice. 
For example, there is a lack of empirical data on the effect of vaccinat-
ing badgers with the licensed vaccine (BadgerBCG) on TB incidence 
in cattle.
At present, the vaccine agent for tackling TB in both cattle and 
badgers is Bacille Calmette-Guérin (BCG), a live attenuated strain of 
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Mycobacterium bovis. This has been given to people as a TB vaccine 
since 1927 and is one of the most widely used of all human vaccines. 
The BCG strain used in the badger and cattle experiments in the UK 
is BCG Danish strain 1331 produced by the Statens Serum institut 
in Copenhagen, Denmark, which is the strain licensed for human 
vaccination in the UK. For simplicity, we will refer to this strain from 
now on as BCG, although not all of the experiments referenced in this 
review use this strain.
The nature of protective immunity to mycobacterial infection is 
complex and still only partly understood. Pathogenic mycobacteria 
evade and exploit the immune system of the host to their advantage 
(Raja 2004), meaning that infected animals do not readily clear the 
infection. As a result of this evasion of the immune system, BCG 
does not induce full protective immunity in all individuals. Thus, a 
proportion of vaccinated humans and animals can still be infected and 
develop disease (Barreto and others 2006, Dye 2013, Waters and oth-
ers 2012). However, laboratory studies have demonstrated that vac-
cination with BCG can reduce the progression and severity of TB and 
the excretion of M bovis in both badgers and cattle (Buddle and others 
1995, Lesellier and others 2011). 
Vaccination of badgers
in areas with a reservoir of infection in badgers, the goal of badger 
vaccination is to reduce the pressure of infection from badgers to 
cattle such that transmission between the two is eliminated or 
significantly reduced. A vaccine has the potential to achieve that 
goal either through preventing infection altogether or by reducing 
the infectiousness of vaccinated badgers that become infected with 
M bovis. Badger vaccination could also have a role in protecting 
uninfected badger populations at risk of disease spread, for example, 
in the face of advancing disease at the edge of bovine TB endemic 
areas. Both scenarios are novel, as vaccination has, so far, not been 
used extensively to control chronic bacterial infections such as TB in 
wildlife (Blancou and others 2009). The only available TB vaccine for 
badgers (BadgerBCG) was licensed by the UK competent authority 
the veterinary Medicines Directorate (vMD) in 2010, following 10 
years of studies carried out by the AHvLA (formerly the veterinary 
Laboratories Agency [vLA] and the national Wildlife Management 
Centre of the Food and environment Research Agency, now also 
part of AHvLA). it is an injectable vaccine with a Limited Marketing 
Authorisation and is currently available for use by vets and trained lay 
vaccinators under prescription from a veterinary surgeon. For more 
information see Brown and others (2013). Licensing of BadgerBCG 
required evidence of vaccine safety and efficacy, obtained from 
laboratory and field studies, but the duration of immunity from 
BadgerBCG remains unknown. 
The value of a vaccination campaign can be assessed in three main 
ways, each providing a different measure of success (Blancou and oth-
ers 2009). These are: quantification of vaccine uptake; assessment of 
the immune response in vaccinated individuals; and evaluation of 
the epidemiological consequences of vaccination. in the case of BCG 
vaccination where the vaccine is used as a national disease control 
tool, the principal interest is in the epidemiological consequences 
in cattle and badgers, although this is the hardest measure to assess. 
The likely impact of badger vaccination on TB incidence in cattle is 
poorly understood. Modelling studies have provided predictions of the 
effects of vaccination relative to other interventions (Smith and oth-
ers 2012); however, in the absence of the necessary field data, it is not 
known whether mathematical predictions will be borne out in reality. 
Measuring this empirically and accurately would involve monitoring 
cattle TB incidence in areas where badgers were vaccinated and in 
other areas where they were not, ideally within a large randomised 
and controlled field experiment with an appropriately structured sam-
pling framework.
Protective effect of badger vaccination 
our understanding of the effects of vaccination on badger immune 
responses is derived from laboratory and field studies. Laboratory 
studies with captive badgers supported the claim that the vaccination 
of badgers by injection with BCG significantly reduces the number 
and severity of lesions of tuberculosis caused by M bovis (Lesellier 
and others 2011). The protection afforded to badgers by BCG in 
experimental challenge models such as these is rarely complete 
(defined as the absence of visible pathology and the isolation of 
M bovis from tissues), most likely because of the relatively high infection 
doses used in experimental studies in order to generate reproducible 
levels of infection. Hence the protection afforded in experimental 
challenge models may not reflect the level of protection afforded against 
‘natural challenge’ in the wild, where animals may be exposed to lower 
numbers of virulent bacteria (see experimental evidence for BCG in 
cattle later in this review). The results of a four-year field study of BCG 
in wild badgers were consistent with the direct protective effect of BCG 
observed in experimental studies. individual badgers that initially tested 
negative to a panel of diagnostic tests and were presumed uninfected 
were significantly less likely to subsequently test positive to serological 
and immunological tests for TB following vaccination, compared to 
non-vaccinated control animals (Chambers and others 2011, Carter 
and others 2012). The risk of yielding a positive result was reduced 
by 54 per cent using a combination of diagnostic tests (‘triple test’) to 
detect infection (bacterial culture for M bovis, the Brock (TB) Stat-Pak 
serological test and an interferon-gamma (iFn-γ) test based on the use 
of specific M bovis antigens eSAT-6 and CFP-10). When test results 
were restricted to culture and Stat-Pak, risk was reduced by 76 per cent, 
consistent with an additional impact of vaccination in the prevention 
of disease progression in vaccinated animals that still became infected 
(Carter and others 2012). The ‘triple test’ represents the most sensitive 
panel of tests available to detect infection in a live vaccinated animal, 
whereas positive Stat-Pak and culture results are better indicators of 
more advanced infection.
Although the BadgerBCG field study was relatively small-scale 
and designed primarily as a field safety study, it also demonstrated 
an indirect beneficial effect of vaccination; evidence of the herd 
immunity effect of vaccination, whereby unvaccinated individuals 
are indirectly protected as the vaccine prevents circulation of an infec-
tious agent in susceptible populations by increasing the prevalence of 
immunity (see review by Kim and others [2011]). in this case, non-vac-
cinated cubs captured in vaccinated social groups were significantly 
less likely to test positive to TB when more members of their group 
had been previously vaccinated. When more than a third of the social 
group had been previously vaccinated, the risk of non-vaccinated cubs 
testing positive by culture, Stat-Pak or the iFn-γ test was reduced by 
79 per cent (Carter and others 2012). The most plausible explanation 
for this result is that vaccination had reduced the rate of transmission 
more effectively in social groups where a higher proportion of animals 
had been vaccinated during the four-year study. The indirect protec-
tive effect conferred to non-vaccinated cubs living in such groups was 
evident after the point that they had emerged from the sett, that is, at 
the point at which they could be caught and vaccinated themselves.
There is no evidence of either a beneficial or detrimental effect of 
BCG in infected badgers. Assuming widespread annual deployment, 
the beneficial effects of vaccination should accrue over time as the 
proportion of the population vaccinated increases and animals with 
pre-existing infection die off naturally. There is no empirical evidence 
on the optimal size or duration for a badger vaccination programme. 
Benefits will start to accrue from the onset of immunity and most 
badgers (whether infected with TB or not) are expected to die off 
within five years (Wilkinson and others 2000).
Field delivery of an injectable badger vaccine
BadgerBCG has been deployed in an area of Gloucestershire in each 
of the four years since it was licensed in 2010, as part of the five-year 
Defra-funded Badger vaccine Deployment Project (BvDP) (Defra 
2014b). The BvDP aims to increase knowledge of the practicalities 
and costs of deploying injectable BCG, train lay badger vaccinators 
and build confidence in the principle of badger vaccination. it was not 
designed to estimate the impact of badger vaccination on the incidence 
of TB breakdowns in cattle herds. Up until the end of 2013, 182 lay 
vaccinators from a range of organisations had been trained on the 
bespoke training course built into the BvDP. The project has provided 
an understanding of what is logistically possible in terms of injectable 
vaccine delivery. During the four-month field season in 2013, 834 
badgers were vaccinated over an area of approximately 90 km2 of 
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farmland, encompassing around 100 farm premises. This was carried 
out by a core team of five trapper/vaccinators. nationally, BadgerBCG 
is being deployed under three main models: government agency-led 
(accounting for the largest share); voluntary and community sector 
organisations (with a degree of government support); and commercial 
operators. Combining deployment under all three models, a total of 
2781 badgers were vaccinated in 2013 by 15 organisations. A total of 
6788 badger BCG doses were delivered in england and Wales between 
2010 and 2013 inclusive.
The single largest vaccination project to date was that initiated in 
2012 by the Welsh Government. in the first year of this five-year pro-
ject the Welsh Government vaccinated 1424 badgers over 241 km2 of 
land in west Wales at a cost of approximately £945,000 (Government 
2013). in the second year (2013), 1352 badgers were vaccinated over 
258 km2 at a cost of approximately £927,000 (Government 2014). 
The cost of injectable vaccination has been estimated to be between 
£2000 to £4000 per km2, depending on a wide range of factors 
including the type of organisation delivering the work and environ-
mental factors such as badger density and landscape characteristics. 
incorporating emerging models of deployment into economic analy-
ses will be useful as the costs (and benefits) associated with a gov-
ernment agency-led scheme may differ from a stakeholder initiative 
incorporating voluntary staffing input.
The proportion of the badger population that receives and is pro-
tected by vaccination will influence the rate at which the incidence of 
disease changes in badgers (Wilkinson and others 2004). estimations 
of the proportion of the badger population that is trapped are not 
built into current vaccination projects and therefore this remains 
a knowledge gap. estimated trapping efficacy in triplets during the 
Randomised Badger Culling Trial (RBCT) varied from 35 per cent to 
85 per cent (Smith and Cheeseman 2007). However, this is likely to 
have used a different pattern of trapping over the area and therefore 
may not be directly comparable.
Oral vaccination
The potential of oral vaccination for controlling diseases where there 
is a wildlife reservoir is well illustrated by rabies control, where oral 
vaccination of wildlife has successfully controlled the disease across 
large parts of europe and north America (Brochier and others 1991, 
Slate and others 2005). However, there are important differences 
between vaccination against rabies and TB, not least the degree of 
protective immunity afforded by vaccination and the type of vaccine 
used. The efficacy of oral BCG has been demonstrated in cattle, 
brushtail possums (Trichosurus vulpecula) (Cross and others 2009), 
wild boar (Sus scrofa) (Ballesteros and others 2009) and white-tailed 
deer (Odocoileus virginianus) (nol and others 2008), as well as badgers 
(Murphy and others 2014); each following experimental infection 
with M bovis of captive animals, but also against natural infection in 
wild possums (Tompkins and others 2009). However, the dose for oral 
administration of vaccination is likely to be higher than that given 
parenterally because BCG is killed and degraded in the gut and uptake 
is relatively inefficient (Mortatti and others 1987). experimental 
studies in possums have suggested that in order to generate immunity 
it is necessary for oral BCG to retain viability up until the point of 
delivery to the intestine (Buddle and others 2006). This has been 
facilitated through the formulation of BCG in a lipid matrix that 
provides a stable storage and delivery vehicle (that protects the live 
attenuated bacillus during passage through the stomach) (Cross 
and others 2009). Recent success using heat-inactivated M bovis to 
experimentally vaccinate wild boar orally has increased the number 
of candidate oral vaccines for TB (Garrido and others 2011, Beltran-
Beck and others 2014). 
Since 2005, Defra and the Welsh Government have funded 
research into the development of an oral vaccine for badgers. 
Candidate vaccine baits for badgers have been identified and are being 
evaluated for palatability and efficacy (degree of protection afforded 
to badgers that consume a vaccine bait), but the formulation of the 
vaccine itself is only one element. Linked to this is the need for a prac-
tical deployment strategy that will maximise uptake among the target 
badger population and, as far as possible, minimise consumption by 
other wildlife species or cattle. Uptake of candidate vaccine baits (not 
containing BCG) among badgers has been measured for a range of 
deployment scenarios (for example, spring versus summer deploy-
ments, above ground versus below ground, etc) in different popula-
tions by adding a harmless biomarker to baits, as used successfully 
for wild boar (Ballesteros and others 2013). Following bait feeding, 
badgers are captured and bait uptake rate (proportion of captured badg-
ers that consumed bait) assessed from the presence or absence of the 
biomarker in blood taken from anaesthetised animals. This work has 
produced some encouraging results, but further research on both vac-
cine efficacy and bait deployment needs to be concluded before a final 
candidate vaccine is ready for licensing. 
Current research suggests that baits will need to be deployed at 
all active badger setts in target areas to maximise bait uptake rates (S. 
Carter, unpublished results). This relies on the locations of active setts 
to be known or surveys to be carried out in order to identify them. 
Badgers in bovine TB endemic areas of the UK tend to live in rela-
tively discrete, contiguous group territories that contain, on average, 
one main sett where the majority of the social group spend most of its 
time (neal and Cheeseman 1996, Roper 2010), with groups also hav-
ing additional outlying setts. it is possible that considerably less bait 
could be deployed at the smaller outlying setts, although in practise 
it is difficult to predict the number of badgers in residence in a sett 
from field signs (Wilson and others 2003) and, because of this, current 
research has focused on targeting all active setts.
An oral vaccine will only be a viable control tool if the vaccine 
bait and associated deployment costs are relatively inexpensive, or less 
than that for injectable vaccination. The cost of a vaccine and the 
number of baits deployed at a sett, as well as its efficacy, are likely to 
be key factors in determining the cost effectiveness of oral vaccine 
deployment. Too few baits will result in an ineffective strategy and 
too many will make it economically unviable. The number of baits 
deployed is likely to represent a compromise between maximising 
uptake and minimising cost. Deployment costs may be reduced by 
pre-baiting for a number of days with bait that does not contain the 
vaccine formulation. This may increase vaccine bait uptake by more 
‘neophobic’ badgers, by habituating them to the novel food source 
(Delahay and others 2003). 
The safety of oral vaccine baits in non-target species must also 
be considered before an oral badger vaccine can be licensed for use 
(Blancou and others 2009). Additionally, consumption of baits by 
non-target species has the potential to adversely affect uptake rates by 
badgers, and hence vaccine efficacy, especially if the bait used is attrac-
tive to a wide range of species. A range of wild species, particularly 
rodents, may be exposed to bait deployed at badger setts, but there is 
little evidence from ongoing work with candidate baits to suggest that 
uptake by non-target species will detrimentally affect the uptake of 
vaccine baits by badgers (S. Carter, unpublished results). Consumption 
of an oral vaccine for badgers by cattle needs to be avoided as the inges-
tion of large quantities of BCG can sensitise cattle to the current tuber-
culin skin test (Buddle and others 2005). Current research indicates 
that deployment of bait down setts is the most likely delivery method. 
This approach would substantially reduce the risk of exposure to cat-
tle and other livestock.
Research priorities
The current focus is on generating data that will allow submission 
of at least a Limited Marketing Authorisation application to the 
vMD for an effective, value-for-money oral BCG vaccine. Although 
oral vaccination of badgers has been demonstrated to give protection 
experimentally (Corner and others 2010, Murphy and others 2014), 
it needs to be shown that oral vaccination provides consistent levels 
of protection, and the minimum dose of BCG needed to provide 
protection is yet to be defined. As BCG is currently the largest 
component of the cost of the oral vaccine, this is essential work for 
reducing the overall cost of the oral product. A programme of field 
research aimed at determining the uptake by wild badgers of different 
numbers of biomarked bait is also required. 
Vaccination of cattle
vaccination of cattle against bovine TB could reduce the prevalence, 
incidence and spread of the disease in the cattle population, reducing 
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the number, duration and severity of breakdowns. The ability to 
provide these benefits would be dependent on the effectiveness 
of a vaccination programme in terms of the vaccine used, the way 
in which it was deployed, and on the performance of a compatible 
diagnostic test. 
BCG was first demonstrated to be an efficacious vaccine against 
TB in cattle in 1911, as reviewed in Waters and others (2012). 
extensive work has been carried out since to optimise the dose and 
route of administration of BCG vaccine to cattle. Despite ongoing 
work to develop more efficacious vaccines, BCG remains the best can-
didate vaccine for use in the field in the short to medium term.
Protection from BCG in experimental infection studies
The level of protection afforded by vaccination with BCG has 
been tested in studies where vaccinated cattle were experimentally 
challenged with relatively high doses (1 to 5 x 103 cfu) of M bovis 
administered through the endobronchial route. experimental 
challenge carried out in this way results in highly reproducible 
pathology solely in the lower respiratory tract, which is reflective 
of the pathology seen in the majority of infected cattle in 
Great Britain and in other developed countries. As with badger 
vaccination, the protection afforded to cattle by BCG vaccination in 
experimental challenge models is assessed by comparing the visible 
histopathological and microbiological consequences of infection 
between control and vaccinated animals. However, due to the 
relatively high infection dose in this experimental infection model, 
BCG rarely induces ‘full’ protection (defined as absence of visible 
pathology and ability to isolate M bovis from tissues) but is mainly 
measured by reductions in visible and microscopic pathology as well 
as bacterial burden. Since 2005, the AHvLA and its collaborators 
have carried out a series of experiments comprising 80 vaccinated and 
64 control animals in total. Animals vaccinated with two different 
BCG doses, as early as five days of age and up to nine months old, 
and challenged with M bovis between three and 12 months after 
vaccination were protected, as demonstrated by a significant reduction 
of pathology and bacterial loads. Furthermore, differences were 
observed in the proportion of animals that presented with no visible 
lesions (nvL) between the BCG-vaccinated and unvaccinated control 
animals (29 of 80 vaccinated animals compared to two of 64 controls). 
Some of these nvL animals were also culture-negative, indicating 
that BCG vaccination in cattle can confer complete protection even 
in this very stringent challenge model (see also the description of the 
field experiment results below). The onset of immunity has been 
demonstrated to be as soon as 25 days after vaccination. The levels of 
protection calculated from the median reduction of visible pathology 
scores in vaccinated and control animals in these studies was around 
76 per cent (range 50 to 100 per cent). Therefore, as with BCG in other 
species, it provides cattle a spectrum of protection; some cattle will be 
fully protected, some cattle will exhibit reduced pathology, and some 
cattle will not be protected (for reasons we do not understand). When 
BCG Pasteur strain was delivered to neonatal or very young calves 
(under six weeks old) it was at least as effective as in older animals 
(Buddle and others 2003, Hope and others 2005). 
Protection of cattle by BCG vaccination in this model, while 
unchanged between three and 12 months after vaccination, fell to 
below a statistically significant level when animals were challenged 
24 months after vaccination in an additional experiment. The dura-
tion of immunity based on these experiments employing a severe 
experimental challenge protocol is therefore a minimum of one year, 
and cattle would likely require annual revaccination with BCG based 
on these data alone (Thom and others 2012), although it is possible 
that the duration of immunity in natural transmission settings may 
be longer.
Protection with BCG in natural transmission settings
To provide information about the performance of BCG in a natural 
transmission setting, the AHvLA conducted a limited pilot study 
with collaborators in ethiopia. Thirteen Holstein-Friesian calves 
obtained from a source of cattle with a bovine TB incidence below 
1 per cent were vaccinated with BCG between one and 15 days 
old. They were introduced into an infected herd containing a large 
proportion of skin test reactor cattle, between 25 and 96 days after 
vaccination, along with 14 control calves. vaccinated and control 
animals were slaughtered between 12 and 23 months later and 
examined by postmortem examination and mycobacterial culture 
(Ameni and others 2010). visible pathology was significantly reduced 
in vaccinated cattle. More importantly, 69 per cent of vaccinated 
animals presented with nvL and were culture-negative compared 
to 21 per cent of cattle in the control group. This equates to a level 
of protection against detectable infection, rather than simply a 
reduction of disease, of 61 per cent. When the condemnation rate at 
meat inspection was used as an additional measure, 73 per cent of the 
control calves would have been condemned compared to 23 per cent 
of the vaccinated calves (68 per cent protection). Although this was a 
relatively small pilot experiment, these data suggest that the capability 
of BCG to fully protect against natural infection in the field is higher 
than in experimental infection studies where a more stringent, high 
dose infection protocol is employed, although this hypothesis has yet 
to be confirmed in future experiments. 
As the exposure times of vaccinated calves to the infected donor 
herd varied between 12 and 23 months, this study also provided infor-
mation on the duration of immunity under field conditions. Animals 
that were in contact for 23 months were as protected as animals that 
were in contact for only 10 months, suggesting that the duration of 
infection under these field exposure conditions is longer than the 
12-month minimum duration of infection determined from the exper-
imental studies quoted above. However, as in any field experiment, 
one cannot guarantee that the infection pressure was constant during 
the 23 months of experimentation. The findings of this study need 
to be substantiated, but are consistent with a contemporary study in 
Mexico where cattle were vaccinated with a different strain of BCG 
(Lopez-valencia and others 2010).
Diagnostic test for use in BCG-vaccinated cattle
vaccination with BCG sensitises cattle to tuberculin-based diagnostic 
tests, including the single intradermal comparative cervical skin-test 
(SiCCT) that forms the basis of the UK test and slaughter policy for 
bovine TB. However, while 80 per cent of vaccinated but uninfected 
cattle test positive to the SiCCT six months after vaccination, 
sensitisation wanes to approximately 10 per cent at nine months after 
vaccination (Whelan and others 2011). This sensitisation is the reason 
a diagnostic test is needed, which will allow accurate detection of 
infected cattle among the vaccinated animals (a so-called DivA test; 
differentiate infected from vaccinated animals) and so allow use of a 
BCG-based cattle vaccine for bovine TB disease control alongside a 
test and slaughter programme (vordermeier and others 2011b). 
The primary candidate DivA test is based on the iFn-γ test plat-
form, but is modified from the original tuberculin-based iFn-γ test 
that has been used since 2006 in Great Britain to increase the sensi-
tivity of testing in some TB herd breakdowns. instead of tuberculin, 
the DivA iFn-γ test exploits antigens that are present in M bovis but 
whose genes were deleted in BCG during its attenuation, namely the 
eSAT-6 and CFP-10 antigens, reviewed in vordermeier and others 
(2011b). However, this version of the test is not as sensitive as the 
SiCCT. inclusion of the Rv3615c antigen (which is present in the 
BCG genome but is not secreted by BCG) has improved the sensitiv-
ity of the DivA test, because it detects a cohort of infected animals 
that escape detection using eSAT-6 and CFP-10 antigens (Sidders and 
others 2008). The sensitivity of the iFn-γ DivA test using the CFP-10, 
eSAT-6 and Rv3615c antigens was estimated in 75 BCG-vaccinated 
M bovis-infected animals and 179 BCG-vaccinated non-infected ani-
mals, giving estimates of test sensitivity and specificity of 96.0 per 
cent (88.77 to 99.17) and 95.53 per cent (91.38 to 98.05), respective-
ly (Table 1). These data also highlight the poor performance of the 
conventional iFn-γ test in BCG vaccinated animals, which showed 
a test specificity of 71.51 per cent (64.36 to 78.01). The performance 
of the DivA reagents was also evaluated in naturally infected skin-test 
reactor animals and non-infected control animals. The test sensitiv-
ity was 90.43 per cent (83.54 to 95.12) while specificity was 98.70 
per cent (97.55 to 99.40). The effect of repeat BCG vaccination on 
the specificity of the DivA iFn-γ test has been investigated in BCG-
vaccinated non-infected animals and had no impact on the specificity 
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of the DivA iFn-γ test. Constraints on the use of cattle TB vaccines 
in the eU in the field mean that, to date, field trials using BCG vaccine 
have not been possible in the UK. The performance of the vaccine 
and DivA test under UK field conditions is therefore unknown and 
remains to be determined.
Recent progress has also been made on using the DivA antigens 
in a skin test format (Whelan and others 2010). A protein and peptide 
cocktail derived from eSAT-6, CFP-10 and Rv3615c allowed differen-
tiation between M bovis-infected and BCG-vaccinated cattle when 
used as a DivA skin test reagent. Addition of the antigen Rv3020c 
improved the diagnostic sensitivity still further without compromis-
ing specificity in the face of BCG or Johne’s disease vaccination (Jones 
and others 2012). To date, the skin test DivA has been used in fewer 
animals than the iFn-γ DivA test but it offers advantages as it could 
be easier to deploy and offer a better balance between sensitivity and 
specificity than the iFn-γ test platform.
Research priorities
The highest TB vaccine research priority for Defra and the Welsh 
Government is the design of field trials of the cattle vaccine. As 
stated above, development of the vaccine and the DivA test has, to 
date, only been possible in the laboratory in the UK, as the use of 
vaccination against M bovis in cattle is explicitly forbidden in eU 
legislation. in January 2013, the european Commission outlined a 
tentative timetable for the use of TB vaccination in cattle in the UK 
and eU (eU 2014). included in this are large scale field trials of vaccine 
efficacy and DivA test validation. in December 2013, the european 
Food Standards Authority (eFSA) published its opinion to the eU 
Commission on the requirements of these field trials (eFSA Panel on 
Animal Health and Welfare 2013). Defra has recently commissioned 
the design of these field trials taking into account eFSA’s opinion, and 
this work is due to conclude in summer 2014. 
BCG is not yet licensed as a vaccine for use in cattle. in 2012, a 
Marketing Authorisation application was submitted by the AHvLA 
to the vMD for assessment. However, the initial assessment has high-
lighted requirements for additional data that are required before the 
application can progress. These include further safety studies, which 
are underway. The results from these studies will be one of the factors 
that determine whether field trials can be carried out.
After the design process, the field trials themselves could follow. 
This is subject to agreement on the field trial design by the european 
Commission and granting of an Animal Test Certificate (ATC) by the 
vMD, which enables a field trial to be carried out in the UK, as well 
as a cost-benefit assessment. it is too early to know how many cat-
tle herds would be needed in these trials but the scale of the research 
programme is likely to be considerable, spanning the different TB risk 
areas in england and Wales. 
ongoing research aims to improve the sensitivity of the iFn-γ 
DivA test (vordermeier and others 2011a, 2011b) and to seek alterna-
tive cytokine/chemokine or other alternative biomarkers that could 
be used to replace, or be used in conjunction with, the iFn-γ DivA 
test. This work also aims to develop biomarkers that correlate with 
protection. The definition of such biomarkers would accelerate vac-
cine development as their use as surrogates of protection could reduce 
the need for lengthy and costly experimental challenge experiments. 
Several such markers have been identified, including quantification 
of ‘central memory cells’ (vordermeier and others 2009) and produc-
tion of certain cytokines such as iL-22 that predict vaccine efficacy 
when measured after vaccination but before M bovis infection (Bhuju 
and others 2012). in addition, work is ongoing to further develop the 
DivA skin test.
Research is also underway to develop vaccines that offer higher 
levels of protection against TB than vaccination with BCG alone. 
While no single vaccine currently offers equal or superior perfor-
mance to BCG, when used in combination with BCG, several offer 
enhanced protection, for example, recombinant human adenovirus-
vectored mycobacterial antigens (Dean and others 2014), reviewed in 
Buddle and others (2011). Further assessment of this adenovirus-based 
strategy as well as development of other approaches should result in 
vaccine protocols that impart better protection than with BCG alone, 
and could prolong the duration of immunity. A longer-term research 
goal is the development of vaccines that do not sensitise cattle to 
tuberculin-based diagnostic tests. This would allow the SiCCT and 
conventional iFn-γ test to be used alongside vaccination.
Conclusions
vaccination of both badgers and cattle are potentially important 
components of what is necessarily a comprehensive, multifaceted 
eradication programme. However, the difficulties in achieving 
wider use of the currently available injectable badger vaccine and 
deployment of a cattle vaccine and oral badger vaccine are sizeable and 
will take time to overcome. 
Field data suggest that BCG vaccination provides a similar spec-
trum of protection in badgers as well as cattle and other species where-
by some individuals are fully protected, some are partially protected 
by having reduced disease, and the remainder are afforded no protec-
tion at all, but it is not possible to attribute precise figures to these 
categories. For BCG vaccination of both badgers and cattle, there is 
currently no direct experimental evidence of reduced transmission of 
TB to and between cattle. Computer modelling has indicated that sus-
tained badger vaccination campaigns could be beneficial in lowering 
TB incidence in cattle (Smith and others 2012), but empirical data are 
lacking. To be able to quantify this contribution would require addi-
tional data from a large-scale field trial.
We still know relatively little about how oral vaccination against 
M bovis actually works in any species, how it can be optimised, and 
how applicable results in one species are to other species. Until the 
results of ongoing research into an oral badger vaccine are known 
we cannot be certain of the timescale within which an effective and 
affordable oral badger vaccine may be available. As of now, no prod-
ucts are ready for licensing.
Despite the undoubted progress that has been made towards 
the vaccination of cattle against TB, widespread benefit will not be 
realised until the european Commission permits wide scale use of a 
vaccine and associated DivA test. vaccination of cattle is currently 
prohibited under eU legislation because of the incomplete protection 
offered by BCG together with the sensitisation of vaccinated animals 
to the tuberculin skin test (the primary test prescribed under eU legis-
lation for defining the TB status of cattle and cattle herds). Defra and 
the Welsh Government is working with the european Commission 
to enable vaccination of cattle to be conducted in UK field trials, and 
the current redrafting of the eU Animal Health Legislation potentially 
offers the opportunity to change the legislation on the use of cattle TB 
vaccines in the medium to long term.
Table 1: Performance of the interferon-gamma DIVA test
DIVAa B-Ab
BCG vaccinated/experimentally infected
Number positive/total 72/75 70/75
Sensitivity (per cent) 96.03 93.33
95 per cent confidence interval 88.77–99.17 85.15–97.8
BCG vaccinated/not infected
Number positive/total 8/179 51/179
Specificity (per cent) 95.53 71.51
95 per cent confidence interval 91.38–98.05 64.36–78.01
Field reactors
Number positive/total 104/115 110/115
Sensitivity (per cent) 90.43 95.65
95 per cent confidence interval 83.54–95.12 90.15–98.57
Controls 
Number positive/total 9/691 10/691
Specificity (per cent) 98.70 98.55
95 per cent confidence interval 97.55–99.40 97.35-99.30
a Using the DIVA antigens ESAT-6/CFP-10 and/or Rv3615c, b Using bovine and avian 
tuberculins
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The field trials of cattle vaccine offer significant benefits through 
better understanding of vaccine efficacy and DivA test characteris-
tics, but also face substantial challenges relating to legal and practical 
delivery. Given the likely large scale of the vaccine field trial, they 
will need to be supported by a strong cost-benefit case. The ultimate 
endpoint of using BCG in cattle without trade restrictions may not be 
achieved before 2023. This process will also need to involve adoption 
of the DivA test as a trade test by the World organisation for Animal 
Health (oie). 
Use of vaccine in badgers or cattle requires buy-in from key stake-
holders such as veterinarians and farmers. Acceptance is influenced by 
economic considerations and social attitudes, such as perceptions sur-
rounding vaccination. Social research, carried out as part of the BvDP, 
suggests that farmers are cautious about the ability of badger vaccina-
tion to reduce the incidence of TB in cattle and the vast majority of 
farmers do not think it is their responsibility to pay for badger vaccina-
tion (enticott and others 2012). However, around half of the farmers 
interviewed thought that vaccinating badgers was a good thing to do. 
in addition, a study of farmer attitudes towards TB control measures 
suggested that cattle vaccination is the most accepted TB control 
measure (Bennett and Cooke 2005). Research has also shown that cat-
tle farmers have a substantial willingness to pay for a TB cattle vaccine 
(Bennett and Balcombe 2012), but this is dependent on its effective-
ness and cost. To build on this, any cattle vaccine field trials should 
have a substantial social research component to further understand 
the drivers for acceptance by vets and farmers, as this is crucial for a 
successful vaccine policy.
Despite the obstacles presented, much progress has been made on 
the development of TB vaccines. The ongoing drive to eradicate TB 
in england and Wales means we need to use all the disease control 
measures available, and therefore the need to bring effective and cost-
effective vaccines to market that can be used to tackle the problem of 
bovine TB in england and Wales remains an urgent one.
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